Claims for Patent: 10,308,602

Summary for Patent: 10,308,602

Title:	Organoselenium compounds, method for producing same, and pharmaceutical uses thereof in particular as antitumor agents
Abstract:	The invention relates to a selenium compound. Said selenium compound has formula (I), where R.sup.1=alkyl; R.sup.2=H, R.sup.4C(=0), R.sup.4OC(=0), a-aminoacyl, CH.sub.3SeCH.sub.2CH.sub.2CH(NH.sub.2)C(=0), CH.sub.3SeCH.sub.2CH.sub.2CH(OH)C(=0); X=OH, OR.sup.3, NH.sub.2, NR.sup.4R.sup.5, .alpha.-amino acid, CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)NH--, CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)0-; R.sup.3=alkyl; R.sup.4=alkyl, aryl; R.sup.5=H, alkyl, aryl; R.sup.4 and R.sup.5 which can together form a 5- or 6-membered cycloalkyl radical which can comprise a heteroatom; provided that when X=NH-terbutyl, R.sup.2.noteq.C(=0)CH.sub.3. Said compound can be used as a pharmaceutical substance, in particular as an antitumour substance.
Inventor(s):	Yadan; Jean-Claude (Paris, FR), Erdelmeier; Irene (Paris, FR), Moutet; Marc (Paris, FR), Lebel; Remi (Paris, FR)
Assignee:	TETRAHEDRON (Paris, FR)
Application Number:	15/302,633
Patent Claims:	1. A selenium compound having the following general formula (I): ##STR00143## where R.sup.1=a radical selected from a non substituted linear, branched or cyclic saturated carbon containing radical with 1 to 26 carbon atoms, and a substituted linear, branched or cyclic saturated carbon containing radical with 1 to 26 carbon atoms which is substituted by at least one substituent selected from the group consisting of one or more fluorine atoms, one or more carbon-carbon double bonds, at least one OH group, and at least one amino group; R.sup.2=H, R.sup.4C(.dbd.O), R.sup.4OC(.dbd.O), .alpha.-aminoacyl, CH.sub.3SeCH.sub.2CH.sub.2CH(NH.sub.2)C(.dbd.O), CH.sub.3SeCH.sub.2CH.sub.2CH(OH)C(.dbd.O); X=OH, OR.sup.3, NH.sub.2, NR.sup.4R.sup.5, .alpha.-amino acid, CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)NH--, CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)O--; R.sup.3=alkyl; R.sup.4=alkyl, aryl; R.sup.5=H, alkyl, aryl; R.sup.4 and R.sup.5 being capable of forming together a 5- or 6-membered cycloalkyl radical which can comprise a heteroatom; provided that X.noteq.NH-tert-butyl, and any stereoisomers or the pharmaceutically accepted acid or base salts thereof. 2. The selenium compound according to claim 1, wherein R.sup.1 represents a methyl, ethyl, or allyl group. 3. The selenium compound according to claim 1, wherein R.sup.2 is selected from the group consisting of H, .alpha.-aminoacyls, R.sup.4(C.dbd.O), R.sup.4O(C.dbd.O), and CH.sub.3SeCH.sub.2CH.sub.2CH(OH)C(.dbd.O). 4. The selenium compound according to claim 1, wherein X is selected from the group consisting OH, .alpha.-amino acid, CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)NH--, and CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)O--. 5. The selenium compound according to claim 1, wherein R.sup.1 represents a methyl, ethyl, or allyl group; R.sup.2 represents R.sup.4(C.dbd.O), or R.sup.4O(C.dbd.O), and X represents OH or OR.sup.3. 6. The selenium compound according to claim 1, wherein the pharmaceutically acceptable acids are selected from mineral acids comprising hydrochloric, hydrobromic, hydroiodic, sulfuric, and phosphoric acids, or selected from organic acids comprising formic, acetic, trifluoroacetic, propionic, tartaric, benzoic, maleic, fumaric, succinic, citric, oxalic, glyoxylic, and aspartic acids, alkanesulfonic acids comprising methanesulfonic, trifluoromethanesulfonic, and ethanesulfonic, and arylsulfonic acids comprising benzene- and paratoluenesulfonic acids. 7. The selenium compound according to claim 1, wherein the pharmaceutically acceptable bases are selected from mineral bases comprising sodium, lithium, calcium, potassium, magnesium, ammonium or zinc hydroxides, carbonates of alkali or alkaline earth metals comprising sodium, lithium, calcium, potassium, magnesium, ammonium or zinc carbonates and bicarbonates, or organic bases comprising methylamine, propylamine, trimethylamine, diethylamine, triethylamine, N,N-dimethylethanolamine, tris(hydroxymethyl)aminomethane, ethanolamine, pyridine, picoline, dicyclohexylamine, morpholine, proceine, lysine, arginine, histidine, and N-methylglucamine, or else phosphonium salts comprising the alkyl-phosphonium salts, the aryl-phosphonium salts, the alkyl-aryl-phosphonium salts, and the alkenyl-aryl-phosphonium salts, or quaternary ammonium salts. 8. The selenium compound according to claim 1, wherein said compound is selected from the group consisting of: 2-hydroxy-3-(methylseleno)propanoic acid methyl ester; (R)-2-hydroxy-3-(methylseleno)propanoic acid methyl ester; (S)-2-hydroxy-3-(methylseleno)propanoic acid methyl ester; 2-hydroxy-3-(methylseleno)propanoic acid ethyl ester; (S)-(2-hydroxy-3-(methylseleno)propanoic acid benzyl ester; 3-(ethylseleno)-2-hydroxypropanoic acid methyl ester; 2-hydroxy-3-(isobutylseleno)propanoic acid methyl ester; 2-hydroxy-3-(methylseleno)propanoic acid isopropyl ester; 2-hydroxy-3-(methylseleno)propanoic acid; (R)-2-hydroxy-3-(methylseleno)propanoic acid; (S)-2-hydroxy-3-(methylseleno)propanoic acid; 3-ethylseleno-2-hydroxypropanoic acid; 2-hydroxy-3-(isobutylseleno)propanoic acid; dicyclohexylammonium 2-hydroxy-3-(methylseleno)propanoate salt; sodium 2-hydroxy-3-(methylseleno)propanoate salt; magnesium bis(2-hydroxy-3-(methylseleno)propanoate salt; zinc bis(2-hydroxy-3-(methylseleno)propanoate salt; calcium bis(2-hydroxy-3-(methylseleno)propanoate salt; 2-hydroxy-3-(methylseleno)propanamide; N-cyclopropyl-2-hydroxy-3-(methylseleno)propanamide; N-[2-(dimethylamino)ethyl]-2-hydroxy-3-(methylseleno)propanamide; 2-hydroxy-3-(methylseleno)-1-(pyrrolidin-1-yl)propan-1-one; 2-hydroxy-3-(methylseleno)-1-(piperidin-1-yl)propan-1-one; 2-hydroxy-3-(methylseleno)-1-(morpholin-4-yl)propan-1-one; N, N-diethyl-2-hydroxy-3-(methylseleno)propanamide; 2-hydroxy-N-(2-hydroxyethyl)-3-(methylseleno)propanamide; [(2RS)-2-hydroxy-3-methylselenopropanoyl]-(S)-alanine; [(2RS)-2-hydroxy-3-methylselenopropanoyl]-(S)-methionine methyl ester; [(2RS)-2-hydroxy-3-methylselenopropanoyl]-(S)-methionine; [(2R)-2-hydroxy-3-methylselenopropanoyl]-(S)-methionine methyl ester; [(2R)-2-hydroxy-3-methylselenopropanoyl]-(S)-methionine; [(2S)-2-hydroxy-3-methylselenopropanoyl]-(S)-methionine methyl ester; [(2S)-2-hydroxy-3-methylselenopropanoyl]-(S)-methionine; N(.alpha.)-[(2RS)-2-hydroxy-3-methylselenopropanoyl]-N(.omega.)-tert-buto- xycarbonyl-(S)-lysine methyl ester; N(.alpha.)-[(2RS)-2-hydroxy-3-methylselenopropanoyl]-N(.omega.)-fluorenyl- methyloxycarbonyl-(S)-lysine methyl ester; N(.alpha.)-[(2 RS)-2-hydroxy-3-methylselenopropanoyl]-N(.omega.)-benzyloxycarbonyl-(S)-l- ysine methyl ester; [(2RS)-2-hydroxy-3-methylselenopropanoyl]-(S)-selenomethionine methyl ester; [(2RS)-2-hydroxy-3-methylselenopropanoyl]-(S)-selenomethionine; [(2R)-2-hydroxy-3-methylselenopropanoyl]-(S)-selenomethionine methyl ester; [(2R)-2-hydroxy-3-methylselenopropanoyl]-(S)-selenomethionine; [(2S)-2-hydroxy-3-methylselenopropanoyl]-(S)-selenomethionine methyl ester; [(2S)-2-hydroxy-3-methylselenopropanoyl]-(S)-selenomethionine; 2-(acetyloxy)-3-(methylseleno)propanoic acid; 2-(dodecanoyloxy)-3-(methylseleno)propanoic acid; 2-(benzoyloxy)-3-(methylseleno)propanoic acid methyl ester; 2-(benzoyloxy)-3-(methylseleno)propanoic acid; 3-(methylseleno)-2-[(3'-pyridine)oxycarbonyl]propanoic acid methyl ester; 2-[(tert-butoxycarbonyl)oxy]-3-(methylseleno)propanoic acid methyl ester; 2-[(tert-butoxycarbonyl)oxy]-3-(methylseleno)propanoic acid; (2RS)--[N-(tert-butoxycarbonyl)-S-methionyl]-3-(methylseleno)propanoic acid methyl ester; 4-methylseleno-2-(2'-acetyloxy-3'-methylselenopropanoyl)butyric acid methyl ester; 4-methylseleno-2-(2'-acetyloxy-3'-methylselenopropanoyl)butyric acid; 3-methylseleno-2-(2'-acetoxy-4'-methylselenobutanoyl)propanoic acid methyl ester; 3-methylseleno-2-(2'-hydroxy-4'-methylselenobutanoyl)propanoic acid; 2-(pentanoyloxy)-3-(methylseleno)propanoic acid; 2-(nonanoyloxy)-3-(methylseleno)propanoic acid; 2-(linoleoyloxy)-3-(methylseleno)propanoic acid; 2-(linoleoyloxy)-3-(methylseleno)propanoic acid methyl ester; 2-(pivaloyloxy)-3-(methylseleno)propanoic acid; 2-(3-chloropropanoyloxy)-3-(methylseleno)propanoic acid; 2-{(1H-imidazoyl-4-ylcarbonyl)oxy)}-3-(methylseleno)propanoic acid; 2-(pivaloyloxy)-3-(methylseleno)propanoic acid methyl ester. 9. A method for preparing the selenium compounds of general formula (I), defined in claim 1, wherein it includes the following steps: a) the reaction of a racemic (DL) oxirane-2-carboxylic acid ester or of one of the enantiomers thereof (D or L) which are commercially available, with: either an alkylselenol R.sup.1SeH, which is itself prepared in situ from an alkali metal salt of alkylselenolate of formula R.sup.1--Se-M.sub.1 which is itself obtained by reduction of dialkyl diselenide where M.sub.1 represents an alkali metal atom), which is reacted with ammonium chloride; or a dialkylaluminum alkylselenolate derivative of formula Al(R.sup.1).sub.2SeR.sup.1, which is itself generated in situ from the corresponding trialkylaluminum Al(R.sup.1).sub.3 and elemental selenium Se(0), b) if applicable, one or more of the following reactions or series of reactions: hydrolysis of the ester function, then acidification of the reaction medium in order to obtain the corresponding acids of formula (I) where X=OH; then esterification of the acids of formula (I) or of the alkali metal salts thereof with an alcohol or an alkyl halide in order to obtain the corresponding esters of general formula (I) where X=OR.sup.3, with R.sup.3 as defined above; amidification of the acids of formula (I) with an appropriate amine of formula R.sup.4R.sup.5NH or NH.sub.3 where R.sup.5 is as defined above, in order to obtain the compound of general formula (I) where X=NH.sub.2, NR.sup.4R.sup.5 or .alpha.-amino acid, CH.sub.3SeCH.sub.2CH.sub.2CH(COOH)NH--, esterification, when R.sup.2=H, of the hydroxyl function by an appropriate acid in order to obtain the compound of general formula (I) where OR.sup.2 is different from the OH group; salification by an acid or by a base. 10. The method according to claim 9, wherein the selenium reagent is: either a dialkylaluminum alkylselenolate, in an aprotic polar solvent; or an alkylselenol, generated in situ from metal selenium Se(0) and alkyl lithium, in an aprotic polar solvent, and then put in the presence of ammonium chloride. 11. The method according to claim 9, wherein reaction 1) takes place in an aprotic polar solvent, and in that the subsequent reactions leading to the different compounds of formula (I) include at least one acidification, or esterification, or amidification and salification. 12. A method of carrying out treatment of tumors or cancers comprising: providing at least one selenium compound of formula (I) as defined in claim 1 as a pharmaceutical agent alone or combined with at least one other agent selected from at least one other pharmaceutical agent and at least one other antitumor agent, and carrying out a treatment of the tumors or cancers using the pharmaceutical agent alone or combined with at least one other agent selected from at least one other pharmaceutical agent and at least one other antitumor agent. 13. A pharmaceutical composition, wherein it includes at least one pharmaceutically active ingredient including at least one selenium compound of general formula (I) as defined in claim 1, alone or combined with at least one other pharmaceutically active ingredient. 14. The pharmaceutical composition according to claim 13, wherein the selenium compound of general formula (I) constitutes a pharmaceutically active ingredient for carrying out the treatment of tumors or cancers selected from the group consisting of tumors or cancers of the prostate, of the liver, of the pancreas, of the breast, and of the colon, either alone or in combination with one or more other known anticancer or cytotoxic agents, either by pre-administration or by co-administration. 15. The pharmaceutical composition according to claim 13, wherein at least one of the other anticancer agents is selected from the following compounds: aminoglutethimide, estramustine, medroxyprogesterone acetate, leuprolide, flutamide, toremifene, matrix metalloproteinase inhibitors; VEGF inhibitors selected from the group comprising anti-VEGF antibodies (Avastin (R)) and the small molecules selected from the group comprising ZD6474 and SU6668, vatalanib, BAY-43-9006, SU11248, CP-547632 and CEP-7055, the SA-1 and SA-2 inhibitors selected from the group comprising the anti-HER2 antibodies (Herceptin), EGFR inhibitors selected from the group comprising gefitinib, erlotinib, ABX-EGF, EMD72000, 11F8, and cetuximab, Eg5 inhibitors selected from the group comprising SB-715992, SB-743921, and MKI-833; PAN inhibitors selected from the group comprising canertinib, EKB-569, CI-1033, AEE-788, and XL-647; kinase inhibitors selected from the group comprising 2C4, and GW-572016, dasatinib, bicalutamide, tamoxifen, MAPK kinase inhibitors, PI3 kinase inhibitors, PDGF inhibitors selected from the group comprising imatinib, anti-angiogenic agents and the antivascular agents, receptor and non-receptor tyrosine kinase inhibitors, inhibitors of integrin signaling; tubulin, anticancer agents selected from the group comprising vinblastine, vincristine, vinorelbine, vinflunine, paclitaxel, docetaxel, 7-O-methylthiomethylpaclitaxel, 4-deacetyl-4-methylcarbonatepaclitaxel, C-4 methyl carbonate paclitaxel, epothilone A, epothilone B, epothilone C, epothilone D, deoxyepothilone A, deoxyepothilone B, oxabicyclo[14.1.0]-heptadecane-5-9-dione (ixabepilone), leucovorin, tegafur, CDK inhibitors, antiproliferative cell cycle inhibitors, epidophyllotoxin, etoposide, VM-26; anti-neoplastic enzymes, topoisomerase I or II inhibitors selected from the group comprising camptothecin, topotecan, SN-38, procarbazine, mitoxantrone; platinum coordination complexes selected from the group comprising cisplatin, carboplatin and oxaliplatin, purine antagonists selected from the group comprising 6-thioguanine and 6-mercaptopurine, and glutamine antagonists. 16. The pharmaceutical composition according to claim 13, wherein at least one of the other cytotoxic agents is selected from at least one compound that follows: cyclophosphamide, doxorubicin, daunorubicin, mitoxantrone, melphalan, hexamethyl melamine, thiotepa, cytarabine, idatrexate, trimetrexate, dacarbazine, L-asparaginase, bicalutamide, leuprolide, pyridobenzoindole derivatives, the interferons, the interleukins. 17. The pharmaceutical composition according to claim 13, wherein it includes at least one selenium compound of formula (I) at a concentration between 0.02% and 0.15% by weight in selenium equivalent. 18. The pharmaceutical composition according to claim 13, wherein it includes at least one pharmaceutically acceptable carrier and a therapeutically effective amount of one or more of the selenium compounds selected from the group consisting of a selenium compound as defined in claim 1, of a stereoisomer thereof, of a tautomer thereof, and of a pharmaceutically acceptable salt thereof, said carrier consisting essentially of: an injectable or drinkable solution, a solid medium composed of one or more excipients which are selected from the group consisting of vitamins, natural antioxidants, L-ergothioneine, mineral salts, mono-, di- or polysaccharides, folic acid, vitamins B.sub.6, vitamin E, vitamin C, lactose, starch. 19. The pharmaceutical composition according to claim 13, wherein it is formulated for a route of administration selected from the oral route, intravenous route, parenteral route, topical route selected from a transdermal route, a nasal route, an ocular route, and inhalation. 20. The pharmaceutical composition according to claim 13, wherein said at least one selenium compound of formula (I) is selected from the group consisting of ##STR00144## 21. The pharmaceutical composition according to claim 20, wherein said at least one selenium compound of formula (I) is incorporated in an effective amount to treat a tumor or cancer selected from the group consisting of a tumor or cancer of the prostate, a tumor or cancer of the liver, a tumor or cancer of the pancreas, a tumor or cancer of the breast, and a tumor or cancer of the colon. 22. The method of claim 12, wherein said at least one selenium compound of formula (I) is selected from the group consisting of ##STR00145## 23. The method according to claim 22, wherein said at least one selenium compound of formula (I) is incorporated in an effective amount to treat a tumor or cancer selected from the group consisting of a tumor or cancer of the prostate, a tumor or cancer of the liver, a tumor or cancer of the pancreas, a tumor or cancer of the breast, and a tumor or cancer of the colon.

Details for Patent 10,308,602

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2034-04-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2034-04-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2034-04-08
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004		2034-04-08